CClinicalTrials.gg
CompletedNCT02290899Updated Aug 10, 2017

Modulation of Behavioral Inhibition in Attention Deficit Hyperactivity Disorder

An observational study in ADHD, sponsored by Rhode Island Hospital. Completed at 1 site in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-08-10.

Sponsored by Rhode Island Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
30
Ages
10 Years to 17 Years
Sex
All
01

Study summary

The main purpose of this study is to investigate how the brain responds to a procedure known as transcranial direct current stimulation (tDCS) and how tDCS affects performance on a behavioral task. Research suggest that this procedure leads to improvement in brain and behavioral measures of inhibitory control (controlling impulses) in healthy control participants. The investigators want to explore whether the same improvement will be seen in kids with ADHD.

02

Conditions studied

  • ADHD

Keywords

  • Attention Deficit Hyperactivity Disorder (ADHD)
03

In context

Hyperkinesis

729 studies on the registry are indexed under Hyperkinesis; 25 are open to participants now.

This study's enrollment of 30 is below the median of 134 across 122 observational studies indexed under Hyperkinesis.

Browse Hyperkinesis studies →

Lead sponsor

Rhode Island Hospital is the lead sponsor of 187 studies on the registry; 37 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with ADHD

Inclusion criteria

  • Clinical diagnosis of ADHD
  • Parent informed consent and child assent

Exclusion criteria

Exclusion Criteria:

  • Intracranial pathology from a known genetic disorder (e.g., Neurofibromatosis Type 1 (NF1), tuberous sclerosis) or from acquired neurologic disease (e.g. stroke, tumor), cerebral palsy, history of severe head injury, or significant dysmorphology
  • History of fainting spells of unknown or undetermined etiology that might constitute seizures
  • History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family history epilepsy
  • Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
  • History of head injury resulting in prolonged loss of consciousness
  • Substance abuse or dependence within the past six months
  • Chronic treatment with prescription medications that decrease cortical seizure threshold that the patient is unable to withhold from taking during study visits
  • Damaged skin on the scalp (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.)
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
30 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Stop-Signal Task

    Time frame: Immediately following tDCS

07

Study locations

1 site
  • Bradley Hospital
    East Providence, Rhode Island 02915, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02290899
Lead sponsor
Rhode Island Hospital
Collaborators
Nancy Lurie Marks Family Foundation, Bradley Hospital
Responsible party
Sponsor
First posted
Nov 14, 2014
Start date
Jun 2014
Primary completion
Aug 7, 2017
Completion
Aug 7, 2017
Last update
Aug 10, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion